Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
Authors:
- Paul M RidkerPRPaul M Ridker
- John KasteleinJKJohn Kastelein
- Wolfgang KoenigWKWolfgang Koenig
- Jacques GenestJGJacques Genest
- Alberto LorenzattiALAlberto Lorenzatti
- John VarigosJVJohn Varigos
- Peter SiostrzonekPSPeter Siostrzonek
Top Cited Papers
- 1 January 2018
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 391 (10118) , 319-328
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)American Heart Journal, 2011
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- Relative Efficacy of Atorvastatin 80 mg and Pravastatin 40 mg in Achieving the Dual Goals of Low-Density Lipoprotein Cholesterol <70 mg/dl and C-Reactive Protein <2 mg/lJACC, 2005
- Inflammation, Atherosclerosis, and Coronary Artery DiseaseNew England Journal of Medicine, 2005
- C-Reactive Protein Levels and Outcomes after Statin TherapyNew England Journal of Medicine, 2005
- Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery DiseaseNew England Journal of Medicine, 2005
- Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary SyndromesNew England Journal of Medicine, 2004
- Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary EventsNew England Journal of Medicine, 2001
- Therapeutic monoclonal antibodiesThe Lancet, 2000
- Inflammation, Pravastatin, and the Risk of Coronary Events After Myocardial Infarction in Patients With Average Cholesterol LevelsCirculation, 1998